{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:22Z","timestamp":1788479722543,"version":"build-2803163510"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11102-023-01313-8","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T07:02:30Z","timestamp":1680850950000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["How to manage intolerance to dopamine agonist in patients with prolactinoma"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-0972","authenticated-orcid":false,"given":"Matheo Augusto Morandi","family":"Stumpf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Moura Maia","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto Ochman","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter Angelo Sperling","family":"Cescato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-4476","authenticated-orcid":false,"given":"Nina Rosa Castro","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malebranche Berardo Carneiro","family":"Cunha-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-6756","authenticated-orcid":false,"given":"Andrea","family":"Glezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"1313_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s11102-021-01188-7","volume":"24","author":"KJ Yagnik","year":"2021","unstructured":"Yagnik KJ, Erickson D, Bancos I, Atkinson JLD, Choby G, Peris-Celda M et al (2021) Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24:978\u2013988","journal-title":"Pituitary"},{"key":"1313_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW (2011) Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14:222\u2013230","journal-title":"Pituitary"},{"key":"1313_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23:45\u201351","journal-title":"Pituitary"},{"key":"1313_CR5","first-page":"e55","volume":"17","author":"P Iyer","year":"2011","unstructured":"Iyer P, Molitch ME (2011) Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 17:e55\u201358","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"1313_CR6","first-page":"1568","volume":"22","author":"A Wong","year":"2015","unstructured":"Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci Off J Neurosurg Soc Australas 22:1568\u20131574","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"1313_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","volume":"14","author":"J Webster","year":"1996","unstructured":"Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14:228\u2013238","journal-title":"Drug Saf"},{"key":"1313_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000499470","volume":"109","author":"RS Auriemma","year":"2019","unstructured":"Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A (2019) Dopamine agonists: from the 1970s to today. Neuroendocrinology 109:34\u201341","journal-title":"Neuroendocrinology"},{"key":"1313_CR9","doi-asserted-by":"crossref","unstructured":"Crocker AD (1994) Experimental and clinical pharmacology: dopamine- mechanisms of action.Aust Prescr,17\u201321","DOI":"10.18773\/austprescr.1994.023"},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1210\/jcem-63-1-197","volume":"63","author":"CD Malchoff","year":"1986","unstructured":"Malchoff CD, Hughes J, Sen S, Jackson S, Carey RM (1986) Dopamine inhibits the aldosterone response to upright posture. J Clin Endocrinol Metab 63:197\u2013201","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2036.2004.01867.x","volume":"19","author":"M Tonini","year":"2004","unstructured":"Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F (2004) Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19:379\u2013390","journal-title":"Aliment Pharmacol Ther"},{"key":"1313_CR12","doi-asserted-by":"crossref","unstructured":"Kelley BJ, Duker AP, Chiu P (2012) Dopamine Agonists and Pathologic Behaviors. Park Dis, 2012:603631","DOI":"10.1155\/2012\/603631"},{"key":"1313_CR13","doi-asserted-by":"publisher","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J et al (2020) Impulse Control Disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab 105:dgz076","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR14","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","volume":"44","author":"G Beccuti","year":"2021","unstructured":"Beccuti G, Guaraldi F, Natta G, Cambria V, Prencipe N, Cicolin A et al (2021) Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest 44:1699\u20131706","journal-title":"J Endocrinol Invest"},{"key":"1313_CR15","first-page":"1089","volume":"23","author":"A Hamidianjahromi","year":"2022","unstructured":"Hamidianjahromi A, Tritos NA (2022) Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord 23:1089\u20131099","journal-title":"Rev Endocr Metab Disord"},{"key":"1313_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L (2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 180:31\u201340","journal-title":"Eur J Endocrinol"},{"key":"1313_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ando.2020.02.007","volume":"82","author":"CE Stiles","year":"2021","unstructured":"Stiles CE, Steeds RP, Drake WM (2021) Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia. Ann Endocrinol 82:182\u2013186","journal-title":"Ann Endocrinol"},{"issue":"Suppl","key":"1313_CR18","doi-asserted-by":"publisher","first-page":"91S","DOI":"10.1111\/j.1365-2265.1977.tb03343.x","volume":"6","author":"HG Friesen","year":"1977","unstructured":"Friesen HG, Tolis G (1977) The use of bromocriptine in the galactorrhoea-amenorrhoea syndromes: the canadian cooperative study. Clin Endocrinol (Oxf) 6(Suppl):91S\u201399S","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","volume":"39","author":"J Webster","year":"1993","unstructured":"Webster J, Piscitelli G, Polli A, D\u2019Alberton A, Falsetti L, Ferrari C et al (1993) The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf) 39:323\u2013329","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518\u20132522","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","volume":"46","author":"CI Ferrari","year":"1997","unstructured":"Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T et al (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46:409\u2013413","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR22","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247\u20132252","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR23","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1210\/jc.2009-2605","volume":"95","author":"M Ono","year":"2010","unstructured":"Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672\u20132679","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR24","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721\u20134727","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331:904\u2013909","journal-title":"N Engl J Med"},{"key":"1313_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R et al (2008) Diagnosis and management of hyperprolactinemia: results of a brazilian multicenter study with 1234 patients. J Endocrinol Invest 31:436\u2013444","journal-title":"J Endocrinol Invest"},{"key":"1313_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","volume":"14","author":"V dos Santos Nunes","year":"2011","unstructured":"dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:259\u2013265","journal-title":"Pituitary"},{"key":"1313_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2169\/internalmedicine.40.857","volume":"40","author":"T Sabuncu","year":"2001","unstructured":"Sabuncu T, Arikan E, Tasan E, Hatemi H (2001) Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med Tokyo Jpn 40:857\u2013861","journal-title":"Intern Med Tokyo Jpn"},{"key":"1313_CR29","first-page":"33","volume":"13","author":"AJ Al-Husaynei","year":"2008","unstructured":"Al-Husaynei AJ, Mahmood I, Al-Jubori ZS (2008) Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea. Middle East Fertil Soc J 13:33\u201338","journal-title":"Middle East Fertil Soc J"},{"key":"1313_CR30","unstructured":"Pascal-Vigneron V, Weryha G, Bosc M, Leclere J (1995) [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study]. Presse Medicale Paris Fr 1983, 24:753\u2013757"},{"key":"1313_CR31","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/jcpt.13460","volume":"46","author":"MM Fachi","year":"2021","unstructured":"Fachi MM, de Deus Bueno L, de Oliveira DC, da Silva LL, Bonetti AF (2021) Efficacy and safety in the treatment of hyperprolactinemia: a systematic review and network meta-analysis. J Clin Pharm Ther 46:1549\u20131556","journal-title":"J Clin Pharm Ther"},{"key":"1313_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346","journal-title":"N Engl J Med"},{"key":"1313_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1210\/jcem-68-2-336","volume":"68","author":"ML Vance","year":"1989","unstructured":"Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE et al (1989) CV 205\u2013502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 68:336\u2013339","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR34","first-page":"577","volume":"74","author":"T Brue","year":"1992","unstructured":"Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J et al (1992) Effects of the dopamine agonist CV 205\u2013502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 74:577\u2013584","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","volume":"34","author":"L Duranteau","year":"1991","unstructured":"Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM (1991) Effect of the new dopaminergic agonist CV 205\u2013502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol (Oxf) 34:25\u201329","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","volume":"41","author":"L Vilar","year":"1994","unstructured":"Vilar L, Burke CW (1994) Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol (Oxf) 41:821\u2013826","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/09513599409072452","volume":"8","author":"B Merola","year":"1994","unstructured":"Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D et al (1994) Positive response to compound CV 205\u2013502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 8:175\u2013181","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"1313_CR38","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1210\/jcem-72-5-1136","volume":"72","author":"AJ van der Lely","year":"1991","unstructured":"van der Lely AJ, Brownell J, Lamberts SW (1991) The efficacy and tolerability of CV 205\u2013502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 72:1136\u20131141","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2265.1989.tb01263.x","volume":"31","author":"CB Newman","year":"1989","unstructured":"Newman CB, Hurley AM, Kleinberg DL (1989) Effect of CV 205\u2013502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol (Oxf) 31:391\u2013400","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1023\/A:1012884214668","volume":"3","author":"PN Schultz","year":"2000","unstructured":"Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF (2000) Quinagolide in the management of prolactinoma. Pituitary 3:239\u2013249","journal-title":"Pituitary"},{"key":"1313_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","volume":"40","author":"PF van der Heijden","year":"1991","unstructured":"van der Heijden PF, de Wit W, Brownell J, Schoemaker J, Rolland R (1991) CV 205\u2013502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 40:111\u2013118","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1313_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","volume":"32","author":"R Homburg","year":"1990","unstructured":"Homburg R, West C, Brownell J, Jacobs HS (1990) A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205\u2013502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxf) 32:565\u2013571","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR43","first-page":"385","volume":"125","author":"JA Verhelst","year":"1991","unstructured":"Verhelst JA, Froud AL, Touzel R, Wass JA, Besser GM, Grossman AB (1991) Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol (Copenh) 125:385\u2013391","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1313_CR44","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF03343751","volume":"23","author":"DA De Luis","year":"2000","unstructured":"De Luis DA, Becerra A, Lahera M, Botella JI, Valero null, Varela C (2000) A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 23:428\u2013434","journal-title":"J Endocrinol Invest"},{"key":"1313_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF03344963","volume":"17","author":"M Giusti","year":"1994","unstructured":"Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S, Giordano G (1994) A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J Endocrinol Invest 17:51\u201357","journal-title":"J Endocrinol Invest"},{"key":"1313_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G et al (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53\u201360","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR47","first-page":"155","volume":"125","author":"M V\u0115tr","year":"1990","unstructured":"V\u0115tr M, Talas M, Pohanka J, Gaz\u00e1rek F, Fingerov\u00e1 H (1990) Terguride in the treatment of hyperprolactinemia. Acta Univ Palacki Olomuc Fac Med 125:155\u2013160","journal-title":"Acta Univ Palacki Olomuc Fac Med"},{"issue":"Suppl 1","key":"1313_CR48","first-page":"42","volume":"73","author":"A Rojanasakul","year":"1990","unstructured":"Rojanasakul A, Sirimongkolkasem R, Chailurkit LO (1990) The efficacy of lisuride in the treatment of hyperprolactinemic amenorrhea. J Med Assoc Thail Chotmaihet Thangphaet 73(Suppl 1):42\u201346","journal-title":"J Med Assoc Thail Chotmaihet Thangphaet"},{"key":"1313_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJM198309223091205","volume":"309","author":"DL Kleinberg","year":"1983","unstructured":"Kleinberg DL, Boyd AE, Wardlaw S, Frantz AG, George A, Bryan N et al (1983) Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 309:704\u2013709","journal-title":"N Engl J Med"},{"key":"1313_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1012836331506","volume":"3","author":"JJ Orrego","year":"2000","unstructured":"Orrego JJ, Chandler WF, Barkan AL (2000) Pergolide as primary therapy for macroprolactinomas. Pituitary 3:251\u2013256","journal-title":"Pituitary"},{"key":"1313_CR51","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1210\/jcem-72-3-635","volume":"72","author":"SW Lamberts","year":"1991","unstructured":"Lamberts SW, Quik RF (1991) A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 72:635\u2013641","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR52","first-page":"1834","volume":"36","author":"H Stracke","year":"1986","unstructured":"Stracke H, Heinlein W, Horowski R, Schatz H (1986) Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Arzneimittelforschung 36:1834\u20131836","journal-title":"Arzneimittelforschung"},{"key":"1313_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0015-0282(16)45978-9","volume":"37","author":"PG Crosignani","year":"1982","unstructured":"Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P et al (1982) Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride. Fertil Steril 37:61\u201367","journal-title":"Fertil Steril"},{"key":"1313_CR54","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0015-0282(16)59823-9","volume":"49","author":"E Ciccarelli","year":"1988","unstructured":"Ciccarelli E, Touzel R, Besser M, Grossman A (1988) Terguride\u2013a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil Steril 49:589\u2013594","journal-title":"Fertil Steril"},{"key":"1313_CR55","first-page":"375","volume":"27","author":"M Berezin","year":"1991","unstructured":"Berezin M, Avidan D, Baron E (1991) Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 27:375\u2013379","journal-title":"Isr J Med Sci"},{"key":"1313_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cen.12149","volume":"79","author":"A Rastogi","year":"2013","unstructured":"Rastogi A, Bhansali A, Dutta P, Singh P, Vijaivergiya R, Gupta V et al (2013) A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma. Clin Endocrinol (Oxf) 79:409\u2013415","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1313_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1530\/EJE-19-0753","volume":"182","author":"D Kim","year":"2020","unstructured":"Kim D, Ku CR, Kim K, Jung H, Lee EJ (2020) Prolactin \u2264 1 ng\/mL predicts macroprolactinoma reduction after cabergoline therapy. Eur J Endocrinol 182:177\u2013183","journal-title":"Eur J Endocrinol"},{"key":"1313_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/ENDO:28:1:101","volume":"28","author":"G Iv\u00e1n","year":"2005","unstructured":"Iv\u00e1n G, Szigeti-Cs\u00facs N, Ol\u00e1h M, Nagy GM, G\u00f3th MI (2005) Treatment of pituitary tumors: dopamine agonists. Endocrine 28:101\u2013110","journal-title":"Endocrine"},{"key":"1313_CR59","doi-asserted-by":"publisher","first-page":"101268","DOI":"10.1016\/j.beem.2019.04.002","volume":"33","author":"CL Boguszewski","year":"2019","unstructured":"Boguszewski CL, de Castro Musolino NR, Kasuki L (2019) Management of pituitary incidentaloma. Best Pract Res Clin Endocrinol Metab 33:101268","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1313_CR60","first-page":"693","volume":"72","author":"M Vermesh","year":"1988","unstructured":"Vermesh M, Fossum GT, Kletzky OA (1988) Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Obstet Gynecol 72:693\u2013698","journal-title":"Obstet Gynecol"},{"key":"1313_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0015-0282(16)60489-2","volume":"51","author":"OA Kletzky","year":"1989","unstructured":"Kletzky OA, Vermesh M (1989) Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril 51:269\u2013272","journal-title":"Fertil Steril"},{"key":"1313_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/09513599209046395","volume":"6","author":"J Ginsburg","year":"1992","unstructured":"Ginsburg J, Hardiman P, Thomas M (1992) Vaginal bromocriptine\u2013clinical and biochemical effects. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 6:119\u2013126","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"1313_CR63","first-page":"517","volume":"73","author":"E Katz","year":"1989","unstructured":"Katz E, Schran HF, Adashi EY (1989) Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. Obstet Gynecol 73:517\u2013520","journal-title":"Obstet Gynecol"},{"key":"1313_CR64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/00016349109007166","volume":"70","author":"VM Jasonni","year":"1991","unstructured":"Jasonni VM, Raffelli R, de March A, Frank G, Flamigni C (1991) Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand 70:493\u2013495","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1313_CR65","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.fertnstert.2004.09.024","volume":"83","author":"AM Darwish","year":"2005","unstructured":"Darwish AM, Hafez E, El-Gebali I, Hassan SB (2005) Evaluation of a novel vaginal bromocriptine mesylate formulation: a pilot study. Fertil Steril 83:1053\u20131055","journal-title":"Fertil Steril"},{"key":"1313_CR66","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0015-0282(16)58113-8","volume":"65","author":"T Motta","year":"1996","unstructured":"Motta T, de Vincentiis S, Marchini M, Colombo N, D\u2019Alberton A (1996) Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril 65:440\u2013442","journal-title":"Fertil Steril"},{"key":"1313_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000181889","volume":"35","author":"M Moro","year":"1991","unstructured":"Moro M, Maraschini C, Toja P, Masala A, Alagna S, Rovasio PP et al (1991) Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study. Horm Res 35:137\u2013141","journal-title":"Horm Res"},{"key":"1313_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF03348700","volume":"15","author":"B Merola","year":"1992","unstructured":"Merola B, Colao A, Caruso E, Sarnacchiaro F, Lancranjan I, Lombardi G et al (1992) Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. J Endocrinol Invest 15:173\u2013176","journal-title":"J Endocrinol Invest"},{"key":"1313_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/09513599109028448","volume":"5","author":"B Merola","year":"1991","unstructured":"Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I et al (1991) Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 5:267\u2013276","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"1313_CR70","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0015-0282(16)57052-6","volume":"62","author":"JJ Espin\u00f3s","year":"1994","unstructured":"Espin\u00f3s JJ, Rodr\u00edguez-Espinosa J, Webb SM, Calaf-Alsina J (1994) Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics. Fertil Steril 62:926\u2013931","journal-title":"Fertil Steril"},{"key":"1313_CR71","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.fertnstert.2007.09.029","volume":"90","author":"AM Darwish","year":"2008","unstructured":"Darwish AM, El-Sayed AM, El-Harras SA, Khaled KA, Ismail MA (2008) Clinical efficacy of novel unidirectional buccoadhesive vs. vaginoadhesive bromocriptine mesylate discs for treating pathologic hyperprolactinemia. Fertil Steril 90:1864\u20131868","journal-title":"Fertil Steril"},{"key":"1313_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF03349887","volume":"19","author":"E Cicinelli","year":"1996","unstructured":"Cicinelli E, Cignarelli M, Petruzzi D, Matteo MG, Ruccia C, Schonauer LM (1996) Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women. J Endocrinol Invest 19:427\u2013432","journal-title":"J Endocrinol Invest"},{"key":"1313_CR73","doi-asserted-by":"publisher","first-page":"K21","DOI":"10.1530\/EJE-19-0279","volume":"181","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, van Meyel SWF, Pieterman KJ, van Ipenburg JA, Hofland LJ, Donga E et al (2019) Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol 181:K21\u2013K27","journal-title":"Eur J Endocrinol"},{"key":"1313_CR74","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-19-0359","volume":"181","author":"G Raverot","year":"2019","unstructured":"Raverot G, Vasiljevic A, Jouanneau E, Lasolle H (2019) Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. Eur J Endocrinol 181:C1\u2013C3","journal-title":"Eur J Endocrinol"},{"key":"1313_CR75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","volume":"80","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Vasiljevic A, Borson-Chazot F, Raverot G (2019) Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol 80:84\u201388","journal-title":"Ann Endocrinol"},{"key":"1313_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-2007-1011796","volume":"19","author":"MD Bronstein","year":"1987","unstructured":"Bronstein MD, Knoepfelmacher M, Liberman B, Marino R, Germek OA, Schally AV (1987) Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Horm Metab Res Horm Stoffwechselforschung Horm Metab 19:271\u2013274","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"1313_CR77","doi-asserted-by":"crossref","unstructured":"Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary, 23:27\u201337","DOI":"10.1007\/s11102-019-00987-3"},{"key":"1313_CR78","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1055\/a-1525-2131","volume":"53","author":"R Sari","year":"2021","unstructured":"Sari R, Altinoz MA, Ozlu EBK, Sav A, Danyeli AE, Baskan O et al (2021) Treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature. Horm Metab Res Horm Stoffwechselforschung Horm Metab 53:413\u2013424","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"1313_CR79","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1210\/jc.2017-00627","volume":"102","author":"SJ Lin","year":"2017","unstructured":"Lin SJ, Wu ZR, Cao L, Zhang Y, Leng ZG, Guo YH et al (2017) Pituitary tumor suppression by combination of Cabergoline and Chloroquine. J Clin Endocrinol Metab 102:3692\u20133703","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR80","doi-asserted-by":"publisher","first-page":"955100","DOI":"10.3389\/fendo.2022.955100","volume":"13","author":"S Lin","year":"2022","unstructured":"Lin S, Han C, Lou X, Wu ZB (2022) Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report. Front Endocrinol 13:955100","journal-title":"Front Endocrinol"},{"key":"1313_CR81","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.wneu.2018.02.188","volume":"115","author":"X Liu","year":"2018","unstructured":"Liu X, Liu Y, Gao J, Feng M, Bao X, Deng K et al (2018) Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant Prolactinomas: pilot study. World Neurosurg 115:94\u201398","journal-title":"World Neurosurg"},{"key":"1313_CR82","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000514591","volume":"112","author":"LHC Portari","year":"2022","unstructured":"Portari LHC, Correa-Silva SR, Abucham J (2022) Prolactin response to Metformin in Cabergoline-Resistant Prolactinomas: a pilot study. Neuroendocrinology 112:68\u201373","journal-title":"Neuroendocrinology"},{"key":"1313_CR83","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejogrb.2007.05.004","volume":"135","author":"G Tamagno","year":"2007","unstructured":"Tamagno G, Burlacu MC, Daly AF, Beckers A (2007) Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma. Eur J Obstet Gynecol Reprod Biol 135:139\u2013140","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1313_CR84","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574\u20133579","journal-title":"J Clin Endocrinol Metab"},{"key":"1313_CR85","doi-asserted-by":"crossref","unstructured":"Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary, 23:307\u2013313","DOI":"10.1007\/s11102-020-01039-x"},{"key":"1313_CR86","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MCG.0000000000001485","volume":"55","author":"M Heckroth","year":"2021","unstructured":"Heckroth M, Luckett RT, Moser C, Parajuli D, Abell TL (2021) Nausea and vomiting in 2021: a Comprehensive Update. J Clin Gastroenterol 55:279\u2013299","journal-title":"J Clin Gastroenterol"},{"key":"1313_CR87","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol Off J Eur Soc Med Oncol 27:v119\u2013v133","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1313_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3949\/ccjm.89gr.22001","volume":"89","author":"AJ Peixoto","year":"2022","unstructured":"Peixoto AJ (2022) Evaluation and management of orthostatic hypotension: limited data, limitless opportunity. Cleve Clin J Med 89:36\u201345","journal-title":"Cleve Clin J Med"},{"key":"1313_CR89","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1056\/NEJM198003273021313","volume":"302","author":"DG Kissner","year":"1980","unstructured":"Kissner DG, Jarrett JC (1980) Side effects of bromocriptine. N Engl J Med 302:749\u2013750","journal-title":"N Engl J Med"},{"key":"1313_CR90","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0140-6736(77)90656-0","volume":"2","author":"F Maneschi","year":"1977","unstructured":"Maneschi F, Cionini R, Rolla M, Navalesi R (1977) Shock syndrome after bromocriptine. Lancet Lond Engl 2:462\u2013463","journal-title":"Lancet Lond Engl"},{"key":"1313_CR91","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jacc.2018.05.079","volume":"72","author":"R Freeman","year":"2018","unstructured":"Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI (2018) Orthostatic Hypotension: JACC State-of-the-art review. J Am Coll Cardiol 72:1294\u20131309","journal-title":"J Am Coll Cardiol"},{"key":"1313_CR92","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJM197910183011606","volume":"301","author":"D Parkes","year":"1979","unstructured":"Parkes D (1979) Drug therapy: bromocriptine. N Engl J Med 301:873\u2013878","journal-title":"N Engl J Med"},{"key":"1313_CR93","first-page":"23","volume":"34","author":"AM Deane","year":"2019","unstructured":"Deane AM, Chapman MJ, Reintam Blaser A, McClave SA, Emmanuel A (2019) Pathophysiology and treatment of gastrointestinal motility Disorders in the acutely ill. Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr 34:23\u201336","journal-title":"Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr"},{"key":"1313_CR94","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1046\/j.1365-2265.1996.8240834.x","volume":"45","author":"PJ Jenkins","year":"1996","unstructured":"Jenkins PJ, Jain A, Jones SL, Besser GM, Grossman AB (1996) Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy. Clin Endocrinol (Oxf) 45:447\u2013451","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01313-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01313-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01313-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T04:06:33Z","timestamp":1686197193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01313-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01313-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"30 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For publication porpoise patient provided a written informed consent. We thank Dr Mario Padula for reviewing the MRI images of the case reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}